Another report on generic drug pricing in Canada

Further to my last posting on the complexity of generic drug pricing in Canada, I point to a new report, commissioned by the Health Council of Canada with the view to shedding light on generic drug pricing issues, to pr0mote transparency and to encourage public discussion.  This discussion paper is written by SECOR Consulting, and is entitled: Generic Drug Pricing and Access in Canada: What are the implications?. As it says in the Foreword:

"Prescription drugs account for an increasing proportion of Canada’s growing health care system with rising costs that governments in this country are seeking ways to restrain. The greater use of generic drugs, for which Canadians pay some of the highest prices in the world, accounts for a significant portion of these rising costs. The Health Council of Canada commissioned this independent discussion paper to provide Canadians with some further insight into the generic drug sector and potential options to reduce generic drug prices. Prescription drugs account for an increasing proportion of Canada’s growing health caresystem with rising costs that governments in this country are seeking ways to restrain.The greater use of generic drugs, for which Canadians pay some of the highest pricesin the world, accounts for a significant portion of these rising costs.The Health Council of Canada commissioned this independent discussion paper toprovide Canadians with some further insight into the generic drug sector and potential options to reduce generic drug prices."